{
CRISPR Therapeutics AG

Companies

}
Symbol CRSP
Name CRISPR Therapeutics AG
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country Switzerland
State
City Zug
Zipcode 6300
Website http://www.crisprtx.com
Track all markets on TradingView
insider trades and stock performance update for crisper therapeutics
CRISPR Therapeutics' CEO sold shares at an average price of $46.28, totaling $198,680.04, reducing their ownership by 1.86%. General Counsel James R. Kasinger also sold shares, resulting in a 1.71% decrease in their holdings. Insiders have sold 50,382 shares valued at $2,744,179 in the last three months, with 4.10% of the stock owned by insiders. The company reported a quarterly loss of $1.01 EPS, exceeding estimates, while analysts maintain a "Hold" rating with a consensus target price of $77.93.
MarketBeat
CRISPR Therapeutics AG USA James Kasinger Samarth Kulkarni
Finance & Economy, Market Report
09:52 15.12.2024
institutional investors increase stakes in crisper therapeutics amid stock fluctuations
Larson Financial Group LLC and GPS Wealth Strategies Group LLC significantly increased their stakes in CRISPR Therapeutics during the second quarter, with institutional investors now owning 69.20% of the company. The stock recently hit a 52-week low of $43.23, and analysts have mixed ratings, with a consensus "Hold" and an average target price of $77.93. In its latest earnings report, CRISPR posted a loss of $1.01 per share, beating estimates but falling short on revenue expectations.
MarketBeat
CRISPR Therapeutics AG USA James Kasinger Samarth Kulkarni
Finance & Economy, Market Report
20:55 14.12.2024
crisper therapeutics faces challenges despite first mover advantage in gene therapy
CRISPR Therapeutics, a pioneer in gene therapy, faces challenges despite its first FDA-approved CRISPR-based therapy, Casgevy. With shares down 46% from their peak and minimal revenue reported, the company must navigate intense competition and financial losses while aiming for future growth. Investors are advised to proceed with caution until sales momentum is evident.
Barchart.com
United States Dollar Intellia Therapeutics, Inc. Beam Therapeutics Inc. CRISPR Therapeutics AG Vertex Pharmaceuticals Inc CHE Dan Victor Show more
Healthcare, Market Report
16:32 14.12.2024
CRISPR Therapeutics faces challenges despite FDA approval of groundbreaking therapy
CRISPR Therapeutics, a leader in gene therapy, achieved a milestone with the FDA's approval of its Casgevy product for sickle cell disease, marking the first CRISPR-based therapy. Despite a promising pipeline and $1.9 billion in cash, the company faces challenges with slow commercialization and minimal revenue from Casgevy, which has only reached one patient so far. As it prepares for expanded indications and updated efficacy data by 2025, investors remain cautious amid a 46% drop in share value from its 52-week high.
Yahoo Finance
Vertex Pharmaceuticals Inc CRISPR Therapeutics AG USA
Healthcare, Market Report
15:45 14.12.2024
analysts lower earnings estimates for crispr therapeutics amid mixed ratings
CRISPR Therapeutics (NASDAQ: CRSP) has seen a reduction in Q2 2025 earnings estimates to ($1.48) per share, with a full-year consensus of ($5.17) per share. Analysts have mixed ratings, with two sell, eight hold, and nine buy ratings, while the stock is currently trading at $47.78, down 1.8%. Institutional investors hold 69.20% of the company, reflecting ongoing interest despite recent insider selling.
MarketBeat
CRISPR Therapeutics AG CHE James Kasinger Samarth Kulkarni
Finance & Economy, Market Report
13:37 12.12.2024
editas medicine lays off staff and shifts focus to in vivo gene editing
Editas Medicine will lay off 180 employees, about two-thirds of its workforce, as it shifts focus to “in vivo” gene editing after failing to find a partner for its sickle cell therapy. The company is ending development of its lead CRISPR medicine and will share more preclinical data in early 2025.
BioPharma Dive
United States Dollar bluebird bio, Inc. CRISPR Therapeutics AG Editas Medicine, Inc. Baisong Mei Gilmore O’Neill Show more
Technology & Innovation, News Article
01:00 12.12.2024
insider trading activity and earnings forecast for crispr therapeutics
William Blair forecasts CRISPR Therapeutics will report FY2024 earnings of ($4.66) per share, slightly better than the consensus estimate of ($5.17). The company recently posted Q3 earnings of ($1.01) per share, exceeding expectations, but reported revenues significantly below estimates. Analysts maintain a "Hold" rating on the stock, with a mixed outlook reflected in various price targets.
MarketBeat
CRISPR Therapeutics AG Stanley Corwin James Kasinger Samarth Kulkarni Show more
Finance & Economy, Market Report
13:21 11.12.2024
Catherine Wood boosts investment in CRISPR Therapeutics amid biotechnology growth potential
Catherine Wood, founder of ARK Investment Management, acquired 1,623,868 shares of CRISPR Therapeutics AG at $51.17 each, raising her firm's total holdings to 9,122,493 shares, or 4.24% of the portfolio. This move underscores her confidence in the biotechnology sector and CRISPR's gene-editing technologies, despite the company's current overvaluation. CRISPR Therapeutics, valued at $4.19 billion, is a leader in gene editing, with a focus on addressing significant medical needs through innovative therapeutics.
@gurufocus
United States Dollar CRISPR Therapeutics AG CHE Catherine Wood
Technology & Innovation, Market Report
21:30 10.12.2024
crispr therapeutics faces mixed analyst ratings and insider stock sales
CRISPR Therapeutics holds a consensus "Hold" rating with an average target price of $74.94. CEO Samarth Kulkarni recently sold 30,000 shares at $55.62, reducing his stake by 13.24%. The company reported a quarterly loss of $1.01 per share, surpassing estimates, with revenue of $0.60 million. Insider sales totaled 50,382 shares valued at $2.74 million in the last 90 days, while institutional investors own 69.20% of the stock. The stock traded at $51.94, with a 52-week range of $43.42 to $91.10.
MarketBeat
CRISPR Therapeutics AG USA James Kasinger Samarth Kulkarni
Finance & Economy, Market Report
10:33 06.12.2024
healthcare innovation portfolio targets advancements in pharmaceuticals and medical technologies
The convergence of science and technology is transforming healthcare, with Syfe's Healthcare Innovation portfolio offering diversified investment across genomics, biotechnology, pharmaceuticals, healthcare services, and medical devices. This portfolio includes six carefully selected ETFs, providing exposure to leading companies and innovations in the sector, while managing risks associated with long-term healthcare investments. With no minimum investment and low fees, it aims to capitalize on the future of healthcare advancements.
Connect
Masimo Corporation Vertex Pharmaceuticals Incorporated Abbott Laboratories GE HealthCare Technologies Inc. AtriCure, Inc. Regeneron Pharmaceuticals, Inc. Intuitive Surgical, Inc. CRISPR Therapeutics AG Veeva Systems Inc. Johnson & Johnson Cigna Integra LifeSciences Holdings Corporation CVS Health Corporation Stryker Corporation UnitedHealth Group Incorporated Amgen Inc. Penumbra, Inc. Alphatec Holdings, Inc. UCB SA Boston Scientific Corporation Eli Lilly and Company USA BEL Beigene Revolution Medicines Gilead Sciences Exelixis Incyte Show more
Finance & Economy, Market Report
02:52 13.11.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Market Sentiment Analysis Corporate Responsibility & ESG Central Bank Actions Decentralized Finance (DeFi) Innovations Cryptocurrency & Blockchain Regulations Tokenomics and Crypto Economics Banking Regulations Cryptocurrency Regulations Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Funding Rounds & Investments Mergers & Acquisitions Cryptocurrency Developments SEC & Financial Compliance Inflation Rates & CPI Data Real Estate Investments Shareholder Activism
Countries:
USA CHE JPN AUS CAN IND GBR DEU AUT CHN HKG RUS LIE SAU BHR FRA ARG COL FIN NLD
Companies:
Coinbase Global, Inc. Ripples USD Solana USD BlackRock, Inc. Ethereum USD NVIDIA Corporation Cardano USD Tesla, Inc. Apple Inc. Credit Suisse Real Estate Fund Siat MicroStrategy Incorporated Amazon.com, Inc. Sumitomo Corp Google Inc. Bitwise Bitcoin ETF Chainlink USD Palantir Technologies Inc. Tether USDt CNY VAT Group AG Northern Star Resources Ltd
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Canadian Dollar Colombian Peso Singapore Dollar Indian Rupee
People:
Ali Martinez Donald Trump Michael J. Saylor Elon Musk Charles Hoskinson Bill Gates Fred Thiel Jack Dorsey Jacob King Brian Armstrong Aaron Green Gary Gensler Karin Keller-Sutter Mario Nawfal Alan Santana Richard Schueler Roger J. Hamilton Steven Rossi Jane Dietze Brian P. Brooks

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.